These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 30488510)
41. Public Health Benefits of Routine Human Papillomavirus Vaccination for Adults in the Netherlands: A Mathematical Modeling Study. Matthijsse SM; Hontelez JA; Naber SK; Rozemeijer K; de Kok IM; Bakker R; van Ballegooijen M; van Rosmalen J; de Vlas SJ J Infect Dis; 2016 Sep; 214(6):854-61. PubMed ID: 27330051 [TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program. Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550 [TBL] [Abstract][Full Text] [Related]
43. Sociodemographic factors predicting mother's cervical screening and daughter's HPV vaccination uptake. Spencer AM; Roberts SA; Brabin L; Patnick J; Verma A J Epidemiol Community Health; 2014 Jun; 68(6):571-7. PubMed ID: 24567443 [TBL] [Abstract][Full Text] [Related]
44. Associations between prior HPV4 vaccine doses and cervical cancer screening participation. Boone SD; Pinkston CM; Baumgartner KB; Baumgartner RN; Harper SM; Bonham AJ; Paynter CA; Harper DM Cancer Epidemiol; 2016 Jun; 42():108-14. PubMed ID: 27100836 [TBL] [Abstract][Full Text] [Related]
45. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299 [TBL] [Abstract][Full Text] [Related]
46. Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China. Liu Z; Zhang L; Yang Y; Meng R; Fang T; Dong Y; Li N; Xu G; Zhan S J Med Internet Res; 2020 Jun; 22(6):e17446. PubMed ID: 32234696 [TBL] [Abstract][Full Text] [Related]
47. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer. Vetter KM; Geller SE J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182 [TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil. Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154 [TBL] [Abstract][Full Text] [Related]
49. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. Pedersen C; Petaja T; Strauss G; Rumke HC; Poder A; Richardus JH; Spiessens B; Descamps D; Hardt K; Lehtinen M; Dubin G; J Adolesc Health; 2007 Jun; 40(6):564-71. PubMed ID: 17531764 [TBL] [Abstract][Full Text] [Related]
50. Knowledge and Attitude Toward Human Papillomavirus and HPV Vaccination in Iranian Population: A Systematic Review. Taebi M; Riazi H; Keshavarz Z; Afrakhteh M Asian Pac J Cancer Prev; 2019 Jul; 20(7):1945-1949. PubMed ID: 31350949 [TBL] [Abstract][Full Text] [Related]
51. Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations? Kepka D; Berkowitz Z; Yabroff KR; Roland K; Saraiya M Sex Transm Infect; 2012 Oct; 88(6):433-5. PubMed ID: 22522751 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579 [TBL] [Abstract][Full Text] [Related]
53. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years. Wilson SE; Harris T; Sethi P; Fediurek J; Macdonald L; Deeks SL Vaccine; 2013 Jan; 31(5):757-62. PubMed ID: 23246265 [TBL] [Abstract][Full Text] [Related]
54. Would young women attending sexually transmitted disease clinics benefit from human papillomavirus vaccination? An assessment of human papillomavirus DNA and seropositivity from human papillomavirus sentinel surveillance, 2003-2005. Dunne EF; Flagg EW; Unger ER; Hsu K; Ghanen K; Kerndt P; Shlay JC; Koutsky LA; Datta DS; Panicker G; Zaidi A; Weinstock H; Markowitz LE Sex Transm Dis; 2014 Jan; 41(1):46-9. PubMed ID: 24326582 [TBL] [Abstract][Full Text] [Related]
55. Factors influencing the recommendation of the human papillomavirus vaccine by Serbian pediatricians. Nikolic Z; Matejic B; Kesic V; Eric Marinkovic J; Jovic Vranes A J Pediatr Adolesc Gynecol; 2015 Feb; 28(1):12-18. PubMed ID: 25555297 [TBL] [Abstract][Full Text] [Related]
56. HPV vaccination, knowledge, and attitudes among young cervical cancer survivors in the Deep South. Edler M; Fernandez A; Anderson K; Pierce JY; Scalici J; Daniel CL Vaccine; 2019 Jan; 37(4):550-557. PubMed ID: 30598386 [TBL] [Abstract][Full Text] [Related]
57. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females. Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250 [TBL] [Abstract][Full Text] [Related]
59. RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval. Martín-Merino E; Llorente-García A; Montero Corominas D; Huerta-Álvarez C Pharmaceut Med; 2019 Apr; 33(2):135-144. PubMed ID: 31933248 [TBL] [Abstract][Full Text] [Related]
60. Reduced dose human papillomavirus vaccination: an update of the current state-of-the-art. Toh ZQ; Licciardi PV; Fong J; Garland SM; Tabrizi SN; Russell FM; Mulholland EK Vaccine; 2015 Sep; 33(39):5042-50. PubMed ID: 26271829 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]